In November 2009, Merck & Co and Schering-Plough completed its planned merger. The merged companies will operate under the Merck name.
Schering-Plough is a global pharmaceutical company which discovers, develops and markets new therapies and treatment programmes. It also has a animal health business as well as consumer brands of foot care, over-the-counter and sun care products. 
Schering-Plough states that it is beginning a “new chapter” in the company’s transformation. Its acquisition of the Organon BioSciences business from Akzo Nobel, which includes the human health business Organon and Intervet, the animal healthcare and products division, will fit the company strategically, scientifically and financially, it says.
Combining these businesses with Schering-Plough are expected to yield several important benefits: add strength and breadth to its human pharmaceuticals business; make Schering-Plough one of the world’s leading animal health companies; and bring valuable compounds in development to address its late-stage pipeline gap.
Schering-Plough will continue to make investments to support its geographical expansion strategy and plans to make investments to continue driving the growth of key brands worldwide. The company remains focused on controlling its overhead spending and maintaining a “right-sized” sales force for its current opportunities in the US.
With headquarters in Kenilworth, New Jersey, US, Schering-Plough has 55,000 employees and net sales in 2008 of $18.5bn.
ICIS Chemical Business magazine has unveiled the ICIS Top 100 Chemical Companies, with rankings based on 2008 sales.
A PDF of the ICIS Top 100 Chemical Companies is available for download on ICIS connect.
See the article and analysis of the ICIS Top 100 on ICIS news.
Schering-Plough
Company Structure
In November 2009, Merck & Co and Schering-Plough completed its planned merger. The merged companies will operate under the Merck name.
More about Schering-Plough Structure
Schering-Plough
Strategy & Financial Highlights
In August 2009, Schering-Plough approved the merger with Merck & Co. It is believed that by combining the two companies it will create a “strong global health care leader”. Under the name “Merck”, the combined company will be headed by Merck chairman, president and chief executive officer, Richard Clark and have headquarters in Whitehouse Station, New Jersey, US. ICIS also provides you with key financial data listed in table form.
More about Schering-Plough Strategy & Financial Highlights
News:
Get news on Schering-Plough plus the latest chemical news, information, data, market movements and analysis
in one place with ICIS news
Search:
Find details on other chemical companies and suppliers with
ICIS search
Newsletters:
ICIS offers a range of FREE e-newsletters to ensure that you don't miss out on the latest development and key market intelligence in your industry. If you want the latest news sent to your inbox, sign up for ICIS e-newsletters today.
Plants and projects:
Find out more about current and planned chemical plants and projects by subscribing to our comprehensive database